Skip to main content
Research funding

Team of international scientific experts to advise on £50 million investment into type 1 diabetes research

The Type 1 Diabetes Grand Challenge – a partnership between the Steve Morgan Foundation, Diabetes UK and JDRF UK– has successfully appointed 17 leading international scientists to advise on its £50 million investment into type 1 diabetes research.
22 November 2022

A grand appointment

The Type 1 Diabetes Grand Challenge – a partnership between the Steve Morgan Foundation, Diabetes UK and JDRF UK– has successfully appointed 17 leading international scientists to advise on its £50 million investment into type 1 diabetes research.

The scientists have joined one of three independent Scientific Advisory Panels each advising on a research area identified as having the greatest potential to transform treatments for type 1 diabetes:

  • The root causes of type 1 diabetes Panel, led by Professor Chantal Mathieu
  • The novel insulins Panel, led by Dr Tim Heise
  • The beta cell replacement Panel, led by Professor Matthias Hebrok

All three Panels are Chaired by Professor Simon Heller, a world-renowned diabetes specialist.

Further information on the Grand Challenge’s scope and ambition, and membership of the Scientific Advisory Panels, can be found on the Partnership’s new website.

The Grand Challenge website

The site also features latest Grand Challenge news, information about funding opportunities and funded projects. When research projects are underway it will also demonstrate and celebrate their impact.

Rachel Connor, Director of Research Partnerships at JDRF UK said: “We’re delighted to welcome so many globally renowned scientists, who are already giving us the benefit of their insight and expertise as we shape this Grand Challenge. They are ensuring the research we support through this game-changing partnership will best meet the needs of people living with type 1. The calibre of membership we’ve been able to attract to the new panels is testament to how thrilling the new research, supported by the partnership, will be.”

Dr Elizabeth Robertson, Director of Research at Diabetes UK said: “We are honoured to have so many of the world’s most distinguished diabetes researchers advising the Type 1 Diabetes Grand Challenge. Their expertise will help to ensure that every penny of the Steve Morgan Foundation’s £50 million gift is invested in bold, innovative research with the greatest potential to improve the lives of people with type 1 diabetes.

“We’re delighted to see the global research community united in their support of the Type 1 Diabetes Grand Challenge and look forward to seeing new, exciting research focusing on accelerating progress towards a cure for type 1 diabetes get underway next year.”

The new website can be found at type1diabetesgrandchallenge.org.uk

Related news

Read more
Nina Willer, who used hybrid closed loop technology through pregnancy, and her child.
Treatment research
7 November 2023

Hybrid closed loop technology set to be made available in England and Wales

The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.

Read more
T cell immune system
Research
6 November 2023

New research highlights the effectiveness of immune therapies for type 1 diabetes

The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.

Read more
Dr Ify Mordi, lead type 1 diabetes researcher
Clinical trials
25 October 2023

JDRF award £1.5 million grant to University of Dundee for type 1 diabetes clinical trial

The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.

Read more
Young person receiving an injection of the immunotherapy drug teplizumab.jpg
Research
18 October 2023

Clinical trial finds teplizumab slows type 1 diabetes in people newly diagnosed 

Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.